Contera Pharma develops new treatment of movement disorders. Focus is on treatment of dyskinesia in Parkinson's disease and tardive dyskinesia.
JM-010 has successfully shown efficacy in Phase IIa cPoc studies in dyskinesia in Parkinson's disease and is now in further development.
Other projects are in late pre-clinical discovery for Parkinson’s disease, dyskinesia in Parkinson's disease and tardive dyskinesia.
JM-012 is a candidate for treatment of early morning akinesia in Parkinson’s disease patients.